Pathological elucidation of VWF-ADAMTS13 and cultivation of novel therapy in Kawasaki disease.
| Project/Area Number |
18K15684
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
TSUJII NOBUYUKI 奈良県立医科大学, 医学部附属病院, 研究員 (00571001)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 川崎病 / ADAMTS13 / T-TAS / shear stress / VWF |
|---|
| Outline of Final Research Achievements |
A high VWF:Ag/ADAMTS13:AC ratio in acute-Kawasaki disease (KD) persisted after primary treatment in non-responders, and unbalanced substrate-to-enzyme ratio appeared to associate with vascular endothelial damage. Analysis of existing mode of ADAMTS13 may help to clarify pathogenesis of IVIG resistance in acute-KD.
Acute KD in children was characterized by PTF (platelet thrombus formation under flow conditions)'s early onset and weak stability. Though the current antiplatelet therapy of acute KD in 1week and 1month by aspirin or flurbiprofen effectively suppresses platelet activation, antiplatelet drugs, such as platelet GP IIb/IIIa receptor inhibitor, might be more reasonable for acute KD due to inhibiting the PTF onset.
|
| Academic Significance and Societal Importance of the Research Achievements |
未だに原因は特定されていない川崎病におけるADAMTS13の動態や病勢への影響についての初めての報告であり、川崎病及びその合併症の原因に迫る一助となる研究成果が得られた。
また、血流下の血小板血栓形成を評価することで、現治療ガイドライン下でのアスピリンの有効性を示したことは一つの成果であり、またより理想的な抗血小板薬の性質を解明したことで、新たな抗血小板薬の選択への一助となることができたと考えられる。
|
Report
(5 results)
Research Products
(8 results)
